Search for a trial

Role of genomic factors on late adverse events after lymphoma

Our main objective is to dissect the genomic determinants of treatment-related adverse events after lymphoma, specifically cardiovascular disease and second malignant neoplasms. As such, we will assess the association of genetic and epigenetic…

An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475
(Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin
Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE
667).

This study has been transitioned to CTIS with ID 2023-504821-38-00 check the CTIS register for the current data. Goal of this study is to determine the optimal balance between maintaining high rates of OS in this group and avoiding the long-term…

AERN study: Abscopal Effect of Radiotherapy and Nivolumab in anti-PD1 Pretreated Relapsed or Refractory classical Hodgkin Lymphoma - An international multicenter Phase II trial

The aim of the trial is to improve efficacy of nivolumab in patients with relapsed or refractory HL previously treated with an anti-PD1 antibody. Primary objective of the trial is to show efficacy of the experimental treatment strategy.Secondary…